2022年12月最新中科院JCR期刊分区表数据（升级版）已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY CRIT REV ONCOL HEMAT LetPub评分 7.6
50人评分
我要评分
声誉 8.8 影响力 6.7 速度 7.0 | |||||||||||||||||||||
| 期刊ISSN | 1040-8428 | 微信扫码收藏此期刊 | ||||||||||||||||||||
| 2021-2022最新影响因子 （数据来源于搜索引擎） | 6.625 点击查看影响因子趋势图 | |||||||||||||||||||||
| 2021-2022自引率 | 3.10%点击查看自引率趋势图 | |||||||||||||||||||||
| h-index | 111 | |||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||
| 期刊简介 | Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy. | |||||||||||||||||||||
| 期刊官方网站 | http://www.croh-online.com/ | |||||||||||||||||||||
| 期刊投稿网址 | http://ees.elsevier.com/croh | |||||||||||||||||||||
| 期刊语言要求 | Language Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service. 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY的语言要求，还能让CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY编辑和审稿人得到更好的审稿体验，让稿件最大限度地被CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710 | |||||||||||||||||||||
| 出版商 | Elsevier Ireland Ltd | |||||||||||||||||||||
| 涉及的研究方向 | 医学-血液学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||
| 出版年份 | 1983 | |||||||||||||||||||||
| 年文章数 | 250点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 10.52% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 0.00% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2021-2022年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） |
| |||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1040-8428%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 偏慢,4-8周 来源Elsevier官网： 平均27.3周 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 一般 来源Elsevier官网： 83% | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||
| 在线出版周期 | 来源Elsevier官网： 平均8.8周 | |||||||||||||||||||||
| 期刊常用信息链接 | ||||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Rare histotypes of epithelial biliary tract tumors: A literature review Author: Sapuppo, Elena; Brunetti, Oronzo; Tessitore, Dalila; Brandi, Giovanni; Di Giovanni, Nicola; Fadda, Guido; Luchini, Claudio; Martini, Maurizio; Quaresmini, Davide; Russo, Antonio; Santarpia, Mariacarmela; Scarpa, Aldo; Scartozzi, Mario; Tuccari, Giovanni; Franchina, Tindara; Silvestris, Nicola Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2023; Vol. 181, Issue , pp. -. DOI: 10.1016/j.critrevonc.2022.103892 PubMed DOI |
| 2. | Changing patterns of neoadjuvant therapy for locally advanced rectal cancer: A narrative review Author: He, Weijing; Li, Qingguo; Li, Xinxiang Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2023; Vol. 181, Issue , pp. -. DOI: 10.1016/j.critrevonc.2022.103885 PubMed DOI |
| 3. | The prognostic impact of tumor-infiltrating B lymphocytes in patients with solid malignancies: A systematic review and meta-analysis Author: Liu, Hao; Li, Zhuoqun; Han, Xuan; Li, Zhujun; Zhao, Yan; Liu, Fenghua; Zhu, Ziyu; Lv, Yi; Liu, Zhijun; Zhang, Nana Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2023; Vol. 181, Issue , pp. -. DOI: 10.1016/j.critrevonc.2022.103893 PubMed DOI |
| 4. | HER2-low breast cancer: Novel detections and treatment advances Author: Wu, Yun; Zhong, Ruiqi; Ma, Fei Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2023; Vol. 181, Issue , pp. -. DOI: 10.1016/j.critrevonc.2022.103883 PubMed DOI |
| 5. | Exosomes in sarcoma: Prospects for clinical applications Author: Ye, Huali; Tan, Linyun; Tu, Chongqi; Min, Li Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2023; Vol. 181, Issue , pp. -. DOI: 10.1016/j.critrevonc.2022.103895 PubMed DOI |
| 6. | NTRK fusions in thyroid cancer: Pathology and clinical aspects Author: Ma, Yanhui; Zhang, Qi; Zhang, Kexin; Liang, Yunzi; Ren, Fangbing; Zhang, Jingwen; Kan, Chengxia; Han, Fang; Sun, Xiaodong Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2023; Vol. 184, Issue , pp. -. DOI: 10.1016/j.critrevonc.2023.103957 PubMed DOI |
| 7. | Impact of age on the overall survival benefits of anti-EGFR-containing regimens in head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials Author: Yuguang Zhao, Wenhui Liu, Meiting Sun, Qiuli Miao, Yingmin Liu, Huimin Tian, Yapin Su, Fujun Han Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, Vol.135, 39-46, DOI:10.1016/j.critrevonc.2019.01.017 DOI |
| 8. | The roles of EBV-encoded microRNAs in EBV-associated tumors Author: Min Dong, Jian-ning Chen, Jun-ting Huang, Li-ping Gong, Chun-kui Shao Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, Vol.135, 30-38, DOI:10.1016/j.critrevonc.2019.01.014 DOI |
| 9. | Corrigendum to “Incidence and clinical parameters associated with eribulin mesylate-induced peripheral neuropathy” [Crit. Rev. Oncol./Hematol. 128 (August) (2018) 110–117] Author: Bin Zhao, Hong Zhao, Jiaxin Zhao Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, Vol.135, 20, DOI:10.1016/j.critrevonc.2019.01.007 DOI |
| 10. | Combination versus mono-therapy as second-line treatment for advanced biliary tract cancer: a systematic review and meta-analysis of published data Author: Jie Ying, Jinfei Chen Journal: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, Vol., , DOI:10.1016/j.critrevonc.2019.01.001 DOI |
|
|
安全保密